SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, at 11:30 A.M. ET.
新澤西州澤西城，2024年10月10日(全球新聞社) -- scynexis，inc.(納斯達克: scyx)，一家生物技術公司，致力於開發創新藥物以克服和預防難以治療和耐藥感染，今天宣佈，總裁兼首席執行官David Angulo博士將於10月17日星期四參加2024年麥斯姆醫療保健虛擬峯會上的爐邊聊天，時間爲上午11:30。
|
Maxim Healthcare Virtual Summit Details: | |
|
Format: |
Fireside chat |
|
Date: |
Thursday, October 17, 2024 |
|
Time: |
11:30 A.M. ET |
| Location: | Virtual |
| 馬克西姆醫療保健虛擬峯會詳情： | |
| 格式： |
爐邊聊天 |
| 日期： |
2024年10月17日星期四 |
| 時間： |
上午11:30 |
| 位置： | 線上舉行 |
To sign up to view the presentation, click here.
點擊這裏註冊查看演示。
1x1 investor meetings will be available after the event upon request through the following link or by contacting your Maxim representative.
請通過以下鏈接或聯繫您的Maxim代表，在活動後可以要求安排1對1的投資者會議。
About SCYNEXIS
關於scynexis
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company's proprietary antifungal platform "fungerps". Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit .
納斯達克代碼爲scyx的生物技術公司scynexis，是一家開創性的生物技術公司，致力於開發創新藥物，幫助數百萬全球患者克服並預防日益產生耐藥性的難治性感染。scynexis正在開發該公司的專有抗真菌平台「fungerps」。ibrexafungerp作爲該新型藥物的首個代表已經被GSk授權。美國食品藥品監督管理局（FDA）已於2021年6月批准BREXAFEMME（ibrexafungerp片劑）用於其在外陰陰道念珠菌病（VVC）方面的首個適應症，並於2022年11月獲得第二個適應症，用於減少複發性VVC的發生率。ibrexafungerp用於治療住院患者的威脅生命的侵襲性真菌感染的後期臨床研究正在進行中。來自該新型藥物的額外抗真菌資產目前處於臨床前和發現階段，包括化合物SCY-247。更多信息，請訪問。
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
聯繫方式:
投資者關係
Irina Koffler
LifeSci Advisors
電話：（646）970-4681
ikoffler@lifesciadvisors.com
譯文內容由第三人軟體翻譯。
